Verici Dx plc (LON:VRCI – Get Free Report)’s share price traded up 15.3% during mid-day trading on Monday . The stock traded as high as GBX 6.98 ($0.09) and last traded at GBX 6.98 ($0.09). 179,121 shares changed hands during trading, a decline of 49% from the average session volume of 354,601 shares. The stock had previously closed at GBX 6.05 ($0.08).
Verici Dx Price Performance
The company has a debt-to-equity ratio of 9.28, a quick ratio of 8.49 and a current ratio of 2.58. The business’s fifty day simple moving average is GBX 7.36 and its 200 day simple moving average is GBX 8.70. The stock has a market cap of £16.98 million, a price-to-earnings ratio of -133.00 and a beta of 1.53.
Verici Dx Company Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Read More
- Five stocks we like better than Verici Dx
- Basic Materials Stocks Investing
- RXO Shares Surge Following New Acquisition Deal
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Pros And Cons Of Monthly Dividend Stocks
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
